

CONTACT – Media:

Amsterdam +31.20.550.4488
Lisbon +351.217.900.029

Brussels +32.2.509.1392
Paris +33.1.70.48.24.45

CONTACT – Investor relations:

+33.1.70.48.24.17

ENTERNEXT PARTNERS WITH FRANCE BIOTECH FOR 2nd EDITION OF “FRENCH LIFE SCIENCE DAYS” IN NEW YORK

Paris/New York – 15 June 2015 – EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs¹, is partnering with France Biotech, an association of entrepreneurs in the life sciences, for the second edition of “French Life Science Days”. A forum for listed French life sciences companies and specialised US investors, the event will take place in New York on Thursday, June 18, following an opening night ceremony on Wednesday, June 17.

French Life Science Days was first held in June 2014, when it drew over 50 US investors and offered 70 face-to-face meetings. It received wide media coverage in France and in the United States.

Life sciences a fast-growing sector—and an EnterNext speciality

Euronext is Europe’s most active market for life sciences—biotechs and medtechs—with 70 issuers representing nearly €14 billion in market capitalisation. Since 2009, life science companies have accounted for 27% of total capital raised in IPOs by small and mid-size companies.

Aware of the potential that the life science sector offers, EnterNext has launched a number of initiatives to raise companies’ profiles with investors. One example is a programme with Morningstar to ensure research coverage of listed companies. Another is the Tech 40 label, which highlights nine tech sector companies that have turned in particularly strong performances.

Strong investor interest

Since the beginning of the year, life science company IPOs have been oversubscribed 200% on average, with portions reserved for retail investors oversubscribed 500%. This is due in part to the fact that the NextBiotech index has outperformed most other European stock market indices in recent years. Since 2009, life science companies have used secondary markets to raise over €1.7 billion to finance innovation and growth, an indication of investors’ keen interest. European investors hold 53% of interests in biotech and medtech companies covered by EnterNext, while American investors hold 45% .²

Celebrating the opening of French Life Science Days, Eric Forest, CEO of EnterNext, said : *“In less than 10 years, Euronext has become the European market of choice for life sciences. We are delighted to support this event, which offers a natural fit with EnterNext’s efforts to forge closer ties between investors and listed*

¹ Small and medium-size companies

² Source: LionShares, May 2015

companies. Meetings like this raise the visibility of companies with US investors—many of whom are already shareholders. Which is further proof of the quality and appeal of French biotech and medtech companies.”

Pierre-Olivier Goineau, Chairman of France Biotech, said : *“This year 18 of our top listed companies will get a chance to present their activities to specialised US investors in one-to-one sessions. Investors in America have shown increasing interest in our companies, which offer breakthrough innovations and are expanding on international markets. France’s life sciences industry is booming, with a steep rise in the number of companies listed that reflects the energy of EnterNext and its teams. We would like to thank our 18 participating companies and partners —Bryan, Garnier & Co, EnterNext, Invest Securities, Jones Day, Mazars, NewCap and The Ruth Group—all of them experts in their fields.”*

Contacts Euronext

Vanessa Stephan: +33 1 70 48 24 42; vstephan@euronext.com

Aïchata Tandjigora: +33 1 70 48 24 43; atandjigora@euronext.com

Contact France Biotech

Haude Costa: +33 1 56 58 10 70; haude.costa@france-biotech.org

About EnterNext

Launched in May 2013, EnterNext is the subsidiary of the Euronext Group designed to develop and promote its stock markets specifically for small and medium-size enterprises (SMEs). Drawing on its pan-European presence, EnterNext brings together all Euronext Group initiatives for companies with market capitalisations under €1 billion, including companies listed in the B and C compartments of its regulated European markets and on Alternext, the market tailored to the needs of SMEs. EnterNext plays an active role in facilitating SMEs' access to financial markets, helping them generate the funds they need to grow at regional, national and pan-European level.

About Euronext

Euronext is the primary exchange in the euro zone with over 1,300 issuers worth €3.2 trillion in market capitalisation, an unmatched blue-chip franchise consisting of 24 issuers in the EURO STOXX 50® benchmark and a strong, diverse domestic and international client base.

Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds (ETFs), Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. Euronext operates regulated markets, Alternext and the Free Market; in addition it offers EnterNext, which facilitates SMEs' access to capital markets.

About France Biotech

France Biotech brings together France’s main life science companies and their expert partners. Its mission is to support the development of French life sciences by advocating for a favorable regulatory and fiscal environment. In 2004, France Biotech successfully lobbied the French government to create a special fiscal status for innovative start-ups and continues to act as an advocate for the French innovative sector. The organization is currently chaired by Pierre-Olivier Goineau, Co-Founder and CEO of ERYTECH Pharma. France Biotech has nearly 200 members and its board of directors is composed of 20 entrepreneurs in the life sciences. For more information: <http://www.france-biotech.org>

Disclaimer

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2015, Euronext N.V. - All rights reserved.